Hormone therapyFDA-approvedFirst-line
Darolutamide
How it works
Blocks the androgen receptor on prostate cancer cells, reducing growth signals and slowing disease progression.
Cancer types
Prostate Cancer— All patients
Efficacy
Studies show that darolutamide can delay disease progression and improve survival in patients with non-metastatic castration-resistant prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Darolutamide and Stereotactic Radiotherapy for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Researchers Investigate Darolutamide's Effect on Prostate Cancer Imaging | Prostate Cancer | phase-1/2 | — | Source → |
| Darolutamide Plus Hormone Therapy for Advanced Prostate Cancer in Everyday Practice | Prostate Cancer | phase-3 | — | Source → |
| Darolutamide Trial for Non-metastatic Prostate Cancer in India | Prostate Cancer | preclinical | — | Source → |
| Testing Darolutamide and ADT Before Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Observing Darolutamide's Effectiveness in Non-metastatic Castration-resistant Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Darolutamide with Hormonal Therapy for High-Risk Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Study of Darolutamide and ADT for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Study of Darolutamide in Combination with Androgen Deprivation Therapy and Docetaxel for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Safety Study of Darolutamide in Men with Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Men with Advanced Prostate Cancer to Receive Darolutamide and Hormone Therapy in Real-world Medical Practice | Prostate Cancer | phase-3 | — | Source → |
| Testing Darolutamide with Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Comparing Darolutamide with Androgen Deprivation Therapy in Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Studying Darolutamide Safety in Korean Men with Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Testosterone and Darolutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Darolutamide's Benefit in Prostate Cancer Treatment | Prostate Cancer | phase-3 | In the Japanese subgroup, the probability that the darolutamide triplet provided greater utility was 0.601 when considering three criteria, and 0.975 when considering four criteria, including time to castration-resistant prostate cancer. | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Darolutamide and Hormone Therapy for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) compared with darolutamide + ADT. | Source → |
| Darolutamide Improves Prostate Cancer Treatment for Black Patients | Prostate Cancer | observational | Darolutamide + ADT resulted in an additional 1.04 (95% uncertainty interval 0.56-1.51) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 [0.48-2.71]). | Source → |
| New Combination Therapy Shows Promise for Prostate Cancer | Prostate Cancer | phase-3 | No significant differences in overall survival were found between the doublet regimen and the control group (hazard ratio: 0.81; 95% confidence interval: 0.59-1.12). | Source → |
| Darolutamide Efficacy in Japanese Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Darolutamide Shows Promise in Treating Advanced Prostate Cancer | Prostate Cancer | phase-2 | The median time to PSA50 in the Darolutamide group was 1.5 months, significantly lower than that in the placebo group (3.0 months). | Source → |
| Darolutamide Improves Prostate Cancer Progression in Phase III Trial | Prostate Cancer | phase-3 | Darolutamide plus hormone therapy reduced the risk of radiological progression or death by 46% versus placebo plus hormone therapy. | Source → |
| Short-term Darolutamide with Radiation Therapy for Prostate Cancer | Prostate Cancer | phase-2 | Six months of darolutamide + EBRT compared with 6 months of ADT + EBRT may be efficient in terms of a biological response. | Source → |
| Darolutamide Resistance Linked to NR5A2/HSD3B1 Pathway | Prostate Cancer | lab-study | — | Source → |
| Triplet Therapy Shows Promise for Prostate Cancer Treatment | Prostate Cancer | meta-analysis | Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival, with a hazard ratio of 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.